Last reviewed · How we verify
Hib-MCC
Hib-MCC is a conjugate vaccine that combines Haemophilus influenzae type b (Hib) polysaccharide with meningococcal C conjugate to stimulate immune protection against both pathogens.
Hib-MCC is a conjugate vaccine that combines Haemophilus influenzae type b (Hib) polysaccharide with meningococcal C conjugate to stimulate immune protection against both pathogens. Used for Prevention of invasive Haemophilus influenzae type b disease, Prevention of invasive meningococcal C disease.
At a glance
| Generic name | Hib-MCC |
|---|---|
| Also known as | MENITORIX® |
| Sponsor | MCM Vaccines B.V. |
| Drug class | Conjugate vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine works by conjugating the Hib capsular polysaccharide to meningococcal C protein carrier, enhancing immunogenicity and inducing both T-cell and B-cell responses. This conjugation approach improves the immune response compared to unconjugated polysaccharide vaccines, particularly in young children, providing protection against invasive Hib and meningococcal C disease.
Approved indications
- Prevention of invasive Haemophilus influenzae type b disease
- Prevention of invasive meningococcal C disease
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (PHASE3)
- Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) (PHASE3)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hib-MCC CI brief — competitive landscape report
- Hib-MCC updates RSS · CI watch RSS
- MCM Vaccines B.V. portfolio CI